.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused boosted progression-free and total survival, leading to FDA approval and also a brand-new procedure alternative for patients.